To ask the Secretary of State for Health and Social Care, whether the NICE guidance on abiraterone produced in 2021 was based on abiraterone's cost in generic form.
The National Institute for Health and Care Excellence’s (NICE) published guidance on abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, which has the reference code TA721, was developed before the patent for a...
Abiraterone